Table 3.
Distribution of myoepithelial and endothelial immunoreactivity
| Immunoreactivitya | 0% | ≤50% | >50% | t-test |
|---|---|---|---|---|
| p63 in normal ductsb | 0 | 0 | 100% | |
| p63 in DCIS | 4% | 52% | 44% | p=.01 |
| CD31 in normal vessels | 0 | 0 | 100% | |
| CD31 in LVI | 75% | 20% | 5% | p=.01 |
| D2-40c in normal lymphatics | 0 | 0 | 100% | |
| D2-40 in LVI | 55% | 34% | 11% | p=.01 |
| p63 in normal vessels/lymphatics | 100% | 0% | 0% | |
| p63 in LVI | 97% | Occasional cells | 0% | p=.05 |
| p63/CD31 in normal vessels | 100% | 0 | 0 | |
| p63/CD31 in LVI | 95% | Occasional cells | 0% | p=.05 |
| p63/D2-40 in normal lymphatics | 100% | 0 | 0 | |
| p63/D2-40 in LVI | 97% | Occasional cells | 0% | p=.05 |
a
A total of 100 ducts, lymphatics and blood vessels were separately counted. Immunoreactivity around these ducts and vessels is recorded as a percentage of circumferential immunoreactivity.
b
Immunoreactivity for the designated marker(s) is recorded as percentage of 100 structures showing the indicated degree of circumferential immunoreactivity.
c
The distribution of two other lymphatic endothelial markers, nuclear Prox-1 and cytoplasmic/membrane VEGFR-3 was similar to D2-40 (p=0.1).